Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4198 - Phenotypic Circulating Tumor Cell (CTC) Classifier of Genomic Instability (GI) Associates with Improved Overall Survival (OS) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients (pts) Receiving Platinum Agents in Addition to Taxanes


10 Sep 2017


Poster display session


Howard Scher


Annals of Oncology (2017) 28 (suppl_5): v269-v294. 10.1093/annonc/mdx370


H. Scher1, R.P. Graf2, A. Jendrisak2, B. McLaughlin3, E. Barnett3, N.A. Schreiber3, J. Lee2, J. Kelvin2, Y. Wang2, M. Landers2, R. Dittamore2

Author affiliations

  • 1 Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 2 Translational Research, Epic Sciences Inc., San Diego/US
  • 3 Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York/US


Abstract 4198


The presence of GI has been associated with DNA Damage Response (DDR) genomics. mCRPC pts with DDR(-) can have treatment (Tx) efficacy with poly ADP ribose polymerase inhibitors (PARPi). Similar Tx benefit for DDR(-) pts has been observed with alkylating agents such as platinum Tx in small cohorts. However, obtaining and sequencing metastatic biopsies is currently not scalable for routine use in the clinic due to accessibility, cost and time to result. We previously developed an imaging-based phenotypic classifier to predict presence of GI from individual CTC morphology and demonstrated that these pts had statistically worse OS when receiving androgen receptor signaling inhibitors (ARSi) or Taxanes. In a separate cohort, the same classifier predicted improved PSA response when pts were treated with a PARPi + ARSi vs. ARSi alone. Here, we examined if GI(+) mCRPC pts can have improved OS when receiving a commonly available and inexpensive platinum chemotherapy.


89 blood samples were collected from mCRPC pts prior to taxane Tx (n = 62) or a combination of taxane + platinum (T+P) (n = 27), and processed utilizing the Epic Sciences platform. Choice of therapy was at the discretion of attending physician without knowledge of CTC results. The percent of predicted GI cells per pt sample (%pGI) was calculated after single-cell characterization. Pts were followed for OS.


Pts receiving a T+P combination had higher CTC burdens and lower PSA levels but otherwise showed similar pre-Tx characteristics to taxane-only pts. In a multivariate model containing %pGI, therapy class, and total CTC burden (to help correct for disease burden and severity), a significant interaction between the T+P combination and increasing %pGI, and increased OS (HR: 0.14, CI: 0.026 to 0.72, p = 0.018) was observed.


The results of this study suggest that in a prospective setting with a balanced cohort, pts with high %pGI might have improved OS on taxanes with the addition of platinum agents. Propspective validation of the signature is planned.

Clinical trial identification

Legal entity responsible for the study



Epic Sciences


H. Scher: Consultant: Medivation, Janssen, Sanofi, Clovis. Grant, research support: Medivation, Janssen. Research collaboration: Epic Sciences. R.P. Graf, A. Jendrisak, J. Lee, J. Kelvin, Y. Wang, M. Landers, R. Dittamore: Employee of Epic Sciences. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.